John Lagus

John is currently the Managing Director of Business Development for Tanner Pharma Group. In this role he is responsible to help grow Tanner’s MAP business, focusing on identification and implementation of strategic partnerships that help expand access to medicines globally.

John has worked in the rare disease or expanded access space for over 25 years in various development, operational, and commercial roles. Before joining Tanner Pharma, John was most recently the Head of Managed Access at Clinigen Group.

Over the past 13 years he has had extensive experience with design, implementation and execution of over 200 global access programs spanning small to large companies, and a wide array of therapeutic areas including oncology, hematology, infectious diseases, and rare diseases. John originally began his career in pharma as a statistician at 3M Pharmaceuticals, and then joined Orphan Medical in 2004 to oversee the development and FDA approval of Antizol for toxic alcohol poisonings. John has a BA in mathematics from St Olaf College, and a MS in statistics from Iowa State University.